@article{JTD1575,
author = {Konstantinos Zarogoulidis and Paul Zarogoulidis and Kaid Darwiche and Kosmas Tsakiridis and Nikolaos Machairiotis and Ioanna Kougioumtzi and Nikolaos Courcoutsakis and Eirini Terzi and Bojan Zaric and Haidong Huang and Lutz Freitag and Dionysios Spyratos},
title = {Malignant pleural effusion and algorithm management},
journal = {Journal of Thoracic Disease},
volume = {5},
number = {Suppl 4},
year = {2013},
keywords = {},
abstract = {Involvement of the pleura in lung cancer is a common manifestation accompanying with reduced life expectancy. Symptoms relief and improvement of the quality of life are the primary goals of the management of malignant pleural effusion (MPE). Histological confirmation is essential for optimal patient management. Lung cancer patients, with life expectancy more than 3 months, resistant to chemotherapy should be treated with thoracentesis, intercoastal tube drainage and installation of a sclerosant agent or pleurodesis through thoracospopic procedures or placement of an indwelling pleura catheter. Talc pleurodesis (sterile asbestos-free graded, particle size >15 μm), as “poudrage” or “slurry” still remains the treatment of choice in patients with MPE resistant to chemotherapy.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/1575}
}